Literature DB >> 11532862

Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphism in squamous cell cancer of head and neck.

S Fronhoffs1, T Brüning, E Ortiz-Pallardo, P Bröde, B Koch, V Harth, A Sachinidis, H M Bolt, C Herberhold, H Vetter, Y Ko.   

Abstract

Although tobacco smoke has been established as a main risk factor in the development of head and neck squamous cell cancer (HNSCC), genetic polymorphisms of xenobiotic metabolizing enzymes are supposed to modulate an individual's susceptibility to smoking-related HNSCC. N-acetyltransferase (NAT) 1 gene is known to be polymorphic and its protein product is implicated in the activation and detoxification of carcinogens, such as aromatic amines, present in tobacco smoke. We developed a rapid and reproducible LightCycler-assisted real-time polymerase chain reaction (PCR) for NAT1 genotyping, which allowed the parallel differentiation of NAT1*3, *4, *10 and *11 alleles and separately of NAT1*14 and *17 alleles within 60 min without the need for further post-PCR processing. In order to investigate the role of the NAT1 gene polymorphism as a risk-modifying factor in HNSCC, we tested for the presence of NAT1*3, *4, *10, *11, *14 and *17 alleles in a case-control study of 291 HNSCC patients and 300 healthy controls of Caucasian origin. Our findings suggest that in Caucasians, the risk of HNSCC is not associated with NAT1 polymorphism. The overall distribution of NAT1 allele frequencies was not significantly different among cases and controls. The presence of the fast acetylator NAT1*10 and NAT1*11 alleles did not significantly increase the risk of HNSCC and no modifying effect of NAT1*10 was observed among smokers. This new approach in NAT1 genotyping substantially increases throughput of sample analysis and, therefore, enhances opportunities to study NAT1 as a risk factor in different cancers in large-scale studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532862     DOI: 10.1093/carcin/22.9.1405

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Nucleotide sequence-based multitarget identification.

Authors:  T Vinayagamoorthy; Kirk Mulatz; Roger Hodkinson
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

2.  Association of CYP1A1 and CYP2D6 gene polymorphisms with head and neck cancer in Tunisian patients.

Authors:  Rim Khlifi; Amine Chakroun; Amel Hamza-Chaffai; Ahmed Rebai
Journal:  Mol Biol Rep       Date:  2014-01-22       Impact factor: 2.316

3.  N-acetyltransferase 1 and 2 gene sequence variants and risk of head and neck cancer.

Authors:  Semra Demokan; Yusufhan Suoglu; Mustafa Gözeler; Deniz Demir; Nejat Dalay
Journal:  Mol Biol Rep       Date:  2009-11-08       Impact factor: 2.316

4.  NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis.

Authors:  Kunyi Zhang; Lijuan Gao; Yuqi Wu; Jianyi Chen; Chengguang Lin; Shaohua Liang; Jianxin Su; Jinming Ye; Xuyu He
Journal:  Int J Clin Exp Med       Date:  2015-06-15

5.  Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects.

Authors:  Teresa Nunes; José F Rocha; Manuel Vaz-da-Silva; Bruno Igreja; Lyndon C Wright; Amílcar Falcão; Luis Almeida; Patricio Soares-da-Silva
Journal:  Drugs R D       Date:  2010

6.  Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453).

Authors:  Manuel Vaz-da-Silva; Teresa Nunes; José F Rocha; Amilcar Falcão; Luis Almeida; Patricio Soares-da-Silva
Journal:  Drugs R D       Date:  2011

Review 7.  Polymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: susceptibility to head and neck cancers.

Authors:  Rim Khlifi; Olfa Messaoud; Ahmed Rebai; Amel Hamza-Chaffai
Journal:  Biomed Res Int       Date:  2013-09-16       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.